Bota Bio Adds $100 Million to B Round for Synthetic Biotech Manufacturing

Bota Bio, a San Francisco-Hangzhou industrial synthetic biotech company, added $100 million to its Series B round. Bota uses biological systems for clean and efficient bio-manufacturing of common household and industrial products. It points out current manufacturing methods cause environmental damage. Bota, whose pipeline includes consumer goods, food, nutrition and pharmaceutical products, wants to promote a sustainable biologic manufacturing processes. The financing was led by Sequoia Capital China. More details... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.